![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 12
Zeitschriftenartikel
Pott, Christiane 
ORCID: https://orcid.org/0009-0005-9260-8340; Jurinovic, Vindi; Trotman, Judith ORCID: https://orcid.org/0000-0001-8009-4593; Kehden, Britta; Unterhalt, Michael; Herold, Michael ORCID: https://orcid.org/0000-0002-6801-3292; Jagt, Richard van der ORCID: https://orcid.org/0000-0001-5706-0109; Janssens, Ann; Kneba, Michael; Mayer, Jiri ORCID: https://orcid.org/0000-0003-0567-9887; Young, Moya; Schmidt, Christian; Knapp, Andrea; Nielsen, Tina; Brown, Helen ORCID: https://orcid.org/0009-0007-3637-891X; Spielewoy, Nathalie; Harbron, Chris; Bottos, Alessia; Mundt, Kirsten; Marcus, Robert; Hiddemann, Wolfgang und Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389
(2023):
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma. A Prospective Analysis of the Phase III GALLIUM Study.
In: Journal of Clinical Oncology
[PDF, 794kB]
ORCID: https://orcid.org/0009-0005-9260-8340; Jurinovic, Vindi; Trotman, Judith ORCID: https://orcid.org/0000-0001-8009-4593; Kehden, Britta; Unterhalt, Michael; Herold, Michael ORCID: https://orcid.org/0000-0002-6801-3292; Jagt, Richard van der ORCID: https://orcid.org/0000-0001-5706-0109; Janssens, Ann; Kneba, Michael; Mayer, Jiri ORCID: https://orcid.org/0000-0003-0567-9887; Young, Moya; Schmidt, Christian; Knapp, Andrea; Nielsen, Tina; Brown, Helen ORCID: https://orcid.org/0009-0007-3637-891X; Spielewoy, Nathalie; Harbron, Chris; Bottos, Alessia; Mundt, Kirsten; Marcus, Robert; Hiddemann, Wolfgang und Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389
(2023):
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma. A Prospective Analysis of the Phase III GALLIUM Study.
In: Journal of Clinical Oncology
[PDF, 794kB]
Herold, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Janssens, Ann; McCarthy, Helen; Tedeschi, Alessandra; Pocock, Chris; Rosta, Andras; Trněný, Marek; Nielsen, Tina G.; Knapp, Andrea; Hiddemann, Wolfgang und Marcus, Robert
(2022):
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial.
In: HemaSphere, Bd. 6, Nr. 3, e699
[PDF, 558kB]
ORCID: https://orcid.org/0000-0002-0749-1389; Janssens, Ann; McCarthy, Helen; Tedeschi, Alessandra; Pocock, Chris; Rosta, Andras; Trněný, Marek; Nielsen, Tina G.; Knapp, Andrea; Hiddemann, Wolfgang und Marcus, Robert
(2022):
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial.
In: HemaSphere, Bd. 6, Nr. 3, e699
[PDF, 558kB]
Casulo, Carla ORCID: https://orcid.org/0000-0003-4998-9932; Dixon, Jesse G.; Le-Rademacher, Jennifer ORCID: https://orcid.org/0000-0002-2234-7430; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Hochster, Howard S. ORCID: https://orcid.org/0000-0002-9893-1529; Hiddemann, Wolfgang; Marcus, Robert; Kimby, Eva; Herold, Michael; Sebban, Catherine; Gyan, Emmanuel ORCID: https://orcid.org/0000-0002-7651-9189; Foon, Kenneth; Nielsen, Tina; Vitolo, Umberto ORCID: https://orcid.org/0000-0001-7772-2747; Salles, Gilles A. ORCID: https://orcid.org/0000-0002-9541-8666; Shi, Qian und Flowers, Christopher R.
(2022):
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
In: Blood, Bd. 139, Nr. 11: S. 1684-1693
ORCID: https://orcid.org/0000-0003-4998-9932; Dixon, Jesse G.; Le-Rademacher, Jennifer ORCID: https://orcid.org/0000-0002-2234-7430; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Hochster, Howard S. ORCID: https://orcid.org/0000-0002-9893-1529; Hiddemann, Wolfgang; Marcus, Robert; Kimby, Eva; Herold, Michael; Sebban, Catherine; Gyan, Emmanuel ORCID: https://orcid.org/0000-0002-7651-9189; Foon, Kenneth; Nielsen, Tina; Vitolo, Umberto ORCID: https://orcid.org/0000-0001-7772-2747; Salles, Gilles A. ORCID: https://orcid.org/0000-0002-9541-8666; Shi, Qian und Flowers, Christopher R.
(2022):
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
In: Blood, Bd. 139, Nr. 11: S. 1684-1693
Hirt, Carsten; Hoster, Eva; Unterhalt, Michael; Hänel, Mathias; Prange-Krex, Gabriele; Forstpointner, Roswitha; Florschütz, Axel; Graeven, Ullrich; Frickhofen, Norbert; Wulf, Gerald; Lengfelder, Eva; Lerchenmüller, Christian; Schlag, Rudolf; Dierlamm, Judith; Fischer von Weikersthal, Ludwig; Ahmed, Asima; Harich, Hanns-Detlev; Rosenwald, Andreas; Klapper, Wolfram; Dreyling, Martin; Hiddemann, Wolfgang und Herold, Michael
(2021):
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients. A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.
In: HemaSphere, Bd. 5, Nr. 7, e600
Casulo, Carla; Dixon, Jesse G.; Ou, Fang-Shu; Hoster, Eva; Peterson, Bruce A.; Hochster, Howard S.; Brice, Pauline; Ladetto, Marco; Hiddemann, Wolfgang; Marcus, Robert; Kimby, Eva; Herold, Michael; Nielsen, Tina; Morschhauser, Franck; Rummel, Mathias; Hagenbeek, Anton; Vitolo, Umberto; Salles, Gilles A.; Shi, Qian und Flowers, Christopher R.
(2021):
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.
In: Blood Advances, Bd. 5, Nr. 6: S. 1737-1745
Hirt, Carsten; Hoster, Eva; Unterhalt, Michael; Haenel, Mathias; Prange-Krex, Gabriele; Forstpointner, Roswitha; Florschuetz, Axel; Graeven, Ullrich; Frickhofen, Norbert; Wulf, Gerald; Lengfelder, Eva; Lerchenmueller, Christian; Schlag, Rudolf; Dierlamm, Judith; Fischer von Weikersthal, Ludwig; Ahmed, Asima; Harich, Hanns-Detlev; Rosenwald, Andreas; Klapper, Wolfram; Dreyling, Martin; Hiddemann, Wolfgang und Herold, Michael
(2021):
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hamatologie und Onkologie and the German Low-Grade Lymphoma Study Group.
In: Hemasphere, Bd. 5, Nr. 7, e600
Mir, Farheen; Mattiello, Federico; Grigg, Andrew; Herold, Michael; Hiddemann, Wolfgang; Marcus, Robert; Seymour, John F.; Bolen, Christopher R.; Knapp, Andrea; Nielsen, Tina und Casulo, Carla
(2020):
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
In: American Journal of Hematology, Bd. 95, Nr. 12: S. 1503-1510
Rutherford, Sarah C.; Herold, Michael; Hiddemann, Wolfgang; Kostakoglu, Lale; Marcus, Robert; Martelli, Maurizio; Sehn, Laurie H.; Trneny, Marek; Trotman, Judith; Vitolo, Umberto; Nielsen, Tina; Mattiello, Federico; Sahin, Deniz; Sellam, Gila und Martin, Peter
(2020):
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA.
In: Blood Advances, Bd. 4, Nr. 8: S. 1589-1593
Budau, Laura; Wilhelm, Christian; Moll, Roland; Jaekel, Jörg; Hirt, Carsten; Doelken, Gottfried; Maschmeyer, Georg; Neubauer, Ellen; Strauch, Konstantin; Burchert, Andreas; Herold, Michael und Neubauer, Andreas
(2019):
Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial.
In: Journal of Cancer Research and Clinical Oncology, Bd. 145, Nr. 8: S. 2149-2156
Seymour, John F.; Marcus, Robert; Davies, Andrew; Gallop-Evans, Eve; Grigg, Andrew; Haynes, Andrew; Herold, Michael; Illmer, Thomas; Nilsson-Ehle, Herman; Soekler, Martin; Duenzinger, Ulrich; Nielsen, Tina; Launonen, Aino und Hiddemann, Wolfgang
(2019):
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
In: Haematologica, Bd. 104, Nr. 6: S. 1202-1208
Hiddemann, Wolfgang; Barbui, Anna Maria; Canales, Miguel A.; Cannell, Paul K.; Collins, Graham P.; Dürig, Jan; Forstpointner, Roswitha; Herold, Michael; Hertzberg, Mark; Klanova, Magdalena; Radford, John; Seymour, John F.; Tobinai, Kensei; Trotman, Judith; Burciu, Alis; Fingerle-Rowson, Günter; Wolbers, Marcel; Nielsen, Tina und Marcus, Robert E.
(2018):
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
In: Journal of Clinical Oncology, Bd. 36, Nr. 23: S. 2395-2404
[PDF, 904kB]
Shi, Qian; Flowers, Christopher R.; Hiddemann, Wolfgang; Marcus, Robert; Herold, Michael; Hagenbeek, Anton; Kimby, Eva; Hochster, Howard; Vitolo, Umberto; Peterson, Bruce A.; Gyan, Emmanuel; Ghielmini, Michele; Nielsen, Tina; Bedout, Sabine de; Fu, Tommy; Valente, Nancy; Fowler, Nathan H.; Hoster, Eva; Ladetto, Marco; Morschhauser, Franck; Zucca, Emanuele; Salles, Gilles und Sargent, Daniel J.
(10. Februar 2017):
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.
In: Journal of clinical oncology, Bd. 35, Nr. 5: S. 552-560